drugset
drugset / Trial / NCT05155306

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

NCT05155306 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the relative bioavailability of the intended Commercial Formulation (iCF) (Test, T) compared with Trial Formulation 2 (TFII) (Reference, R) and to assess potential food effects following oral administration of BI 1358894.

Timeline

Start
2022-01-14
Primary completion
2022-05-16
Completion
2022-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule 100 mg Oral

Indications

No indication recorded.